Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent.
This article describes the efficacy, immunogenicity, and safety of CAIV-T. This vaccine has the potential to significantly contribute to the control of influenza infection and influenza-associated illnesses, including febrile otitis media and lower respiratory disease. When compared with inactivated vaccine, CAIV-T has significant advantages in convenience of administration. The high efficacy of CAIV-T and its efficacy in children against a significantly drifted strain of H3N2 (A/Sydney), a strain not contained in the vaccine, are compelling observations for use of the vaccine in children. Effectiveness in adults was demonstrated using the same vaccine strain against the drifted H3N2 strain. The proposed vaccine administration schedule for healthy individuals aged 9 to 49 years is a single dose administered annually before the winter. For children aged 5 to 8 years, two doses are recommended the first year they are immunized with CAIV-T to ensure protection against all strains contained in the vaccine. Thereafter, a single annual revaccination is sufficient.
Belshe
Robert B
RB
Division of Infectious Diseases and Immunology, Saint Louis University, 3635 Vista Avenue (FDT-8N), St. Louis, MO 63110, USA. belsherb@slu.edu
Mendelman
Paul M
PM
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008875:Middle Aged; D016896:Treatment Outcome
D007252:Influenza Vaccines